Cell therapy

Stem Genomics Announces Partnership with Pluristyx, Leading One-Stop-Shop Solution Provider for High-Quality Cell-Based Therapies

Retrieved on: 
Tuesday, July 18, 2023
Health, Stem Cells, Genetics, General Health, Research, Science, Biotechnology, GMP, Good, Database, Stem, Partnership, Good manufacturing practice, Genetic engineering, IPSC, Genomics, Cell therapy, GTP, Doctor of Philosophy, Genome, CNV, Nested polymerase chain reaction, Duo, PSC, PCR, Vaccine, Management

Pluristyx, Inc. and Stem Genomics SAS today announce the closing of an equity investment and strategic partnership in Stem Genomics.

Key Points: 
  • Pluristyx, Inc. and Stem Genomics SAS today announce the closing of an equity investment and strategic partnership in Stem Genomics.
  • Through the partnership, the companies will offer a unified pathway to allow customers to evaluate the genomic stability of Pluristyx’s pluripotent stem cell (PSC) lines using Stem Genomics’ iCS-digital™ PSC assay.
  • Stem Genomics iCS-digital™ PSC assay, based on highly sensitive digital PCR (dPCR) technology, enables the detection of small size copy number variations (CNVs) indicative of genomic instability.
  • Based on Stem Genomics’ unique SMART database, the iCS-digital™ assay can detect up to 92% of recurrent abnormalities common in iPSCs.

Alveo Technologies Announces Partner Program and Portal, New Enablement Software Suite, Further Empowering Partners in Co-Development of Advanced Molecular Diagnostics

Retrieved on: 
Tuesday, July 11, 2023
Software, Research, Other Health, Professional Services, Technology, Agriculture, Natural Resources, Data Analytics, Science, Veterinary, Biotechnology, Health, Other Science, Partnership, Food, Fraunhofer Society, Cell therapy, Infection, Medicine, LAMP, Sanitation, Water, Diagnosis, Immunology, Development corporation, Asylum Support Partnership, Food security, Farm, Fine chemical, Medical device, Alveo Financial Tower

Furthermore, its newest partnership with the Fraunhofer Institute for Cell Therapy and Immunology IZI extends the platform into the large animal veterinary sector.

Key Points: 
  • Furthermore, its newest partnership with the Fraunhofer Institute for Cell Therapy and Immunology IZI extends the platform into the large animal veterinary sector.
  • Alveo has developed a rapid, handheld, reusable, and rugged multiplexed platform that pairs advanced molecular assays with cloud-enabled data analytics for highly accurate and sensitive real-time disease, pathogen and contaminant detection, analysis, and diagnosis.
  • It utilizes Alveo’s globally patented loop-mediated isothermal amplification (LAMP) method for the direct electrical sensing of nucleic acid amplification.
  • The Partnership Portal facilitates collaboration and gives partners access to all research, training, and development resources required to bring a molecular diagnostic to market.

Putting Patients First: The Quest to Make Anticancer Cell Therapy Accessible to All

Retrieved on: 
Tuesday, July 11, 2023
D, IPSC, Hematology, Culture, Feedback, Cell therapy, Monash University, Cancer, Research, Multimedia, Cell, BTK, Science, Philosophy, Name, Hospital, Patient, Developed country, Quality control, Pharmaceutical industry, BeiGene, Tislelizumab, Zanubrutinib

With the inauguration of a new state-of-the-art cell therapy lab in early 2022, BeiGene is looking to broaden collaboration and expand capability in the field of anticancer cell therapy.

Key Points: 
  • With the inauguration of a new state-of-the-art cell therapy lab in early 2022, BeiGene is looking to broaden collaboration and expand capability in the field of anticancer cell therapy.
  • BeiGene only made its first foray into anticancer cell therapy in June 2021, via a collaboration agreement signed with Shoreline Biosciences, a California-based biotech company specializing in natural killer cell therapies.
  • Dr. Huang emphasized that BeiGene not only sought to develop effective anticancer cell therapies, but was also committed to making such treatments affordable and accessible to all patients in need.
  • However, to make cell therapies widely affordable, allogeneic cell therapy based on induced pluripotent stem cells (iPSC) was likely to be an important focus of research going forward.

Global Cell Therapy Market to 2030: Rising Adoption of Regenerative Medicine Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 27, 2023
Biotechnology, Pharmaceutical, Health, Hospital of the University of Pennsylvania, University, Gene, Follicular lymphoma, Cell therapy, Epithelium, Stem cell, Clinical trial, Cartilage, ClinicalTrials.gov, USD, Allogenic succession, Chondrocyte, Investment, Keratinocyte, Cancer, Cell, Growth, FDA, Society, International Society, Pharmaceutical industry, Medical imaging

The "Cell Therapy Market Size, Share, & Trends Analysis Report 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Therapy Market Size, Share, & Trends Analysis Report 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global cell therapy market size is expected to reach USD 62.39 billion by 2030, expanding at 14.15% CAGR from 2023 to 2030.
  • The market players are witnessing an increasing interest in the development of advanced therapies that are based on tissue, gene, or cell.
  • Allogenic therapy segment is expected to grow significantly in the coming years owing to factors such as high pricing and growth in stem cell banking.

Geron to Host Virtual Investor Event on June 14, 2023

Retrieved on: 
Tuesday, June 6, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Ruxolitinib, Clinic, European Hematology Association, Hematology, Cell therapy, American Society of Clinical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Teaching hospital, Acute myeloid leukemia, ASCO, MDS, Imetelstat, Corporation, Geron Corporation, Risk, EHA, Annual general meeting, Webcast, Society, Pharmaceutical industry

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, will host a virtual investor event on Wednesday, June 14, 2023 at 8:00 a.m. Eastern Time.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, will host a virtual investor event on Wednesday, June 14, 2023 at 8:00 a.m. Eastern Time.
  • Topics to be covered at the event include:
    Summary of new IMerge Phase 3 data in lower risk myelodysplastic syndromes (MDS) featured in 2023 medical meetings.
  • This includes presentation of data at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2023 and upcoming presentations at the European Hematology Association (EHA) Annual Meeting taking place from June 8-11, 2023.
  • An archive of the webcast will be available on the Company’s website for 30 days.

NKILT Therapeutics Announces New Scientific Advisory Board Appointments: Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as Advisor

Retrieved on: 
Tuesday, June 6, 2023
Lymphoma, SAB, Drug development, University, Genetic engineering, Therapy, Gene, Stanford University, CSO, Cell therapy, CIR, Center for Cell and Gene Therapy, Baylor University, Cancer, United States Air Force Scientific Advisory Board, NK, Research, Chimera, Doctor of Philosophy, Associate, Acute myeloid leukemia, CAR, AML, MD, Patient, Pathology, Cell, Baylor College of Medicine, American Society of Gene and Cell Therapy, Bone marrow, Alloimmunity, Immunology, Leukemia, Haematopoietic system, Society, Pharmaceutical industry, Medicine

HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their Scientific Advisory Board (SAB) of Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as scientific advisor.

Key Points: 
  • HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their Scientific Advisory Board (SAB) of Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as scientific advisor.
  • Chairman Saar Gill, MD, PhD – Dr. Gill is Associate Professor of Medicine in the division of hematology-oncology at the University of Pennsylvania.
  • He trained in clinical hematology in his native Australia, followed by a postdoctoral fellowship at Stanford University.
  • Since 2011, he has been working on developing genetically engineered immune cells for the treatment of cancer.

Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation

Retrieved on: 
Friday, May 19, 2023
Inflammation, CELU, Cell therapy, Cell, Proteomics, Fistula, Messenger, Regenerative medicine, Society, Disease, Pharmaceutical industry, Gene, Instituto de Biologia Molecular e Celular, Patient

FLORHAM PARK, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced results from an exploratory analysis of Phase 1 data evaluating alterations in gene and protein signatures associated with reduced inflammation and fistula formation resulting from therapy with mesenchymal‐like adherent stromal cells (MLASCs) in adult patients with Crohn’s disease (CD). These data were presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy, which is being held May 16-20th in Los Angeles.

Key Points: 
  • (Placental‐Derived Mesenchymal‐Like Adherent Stromal Cell (MLASC) Therapy Results in Alterations in Gene and Protein Signatures Associated with Inflammation and Fistula Formation in Patients with Crohn’s Disease, Kilcoyne, et al., Poster Session 1111.)
  • In this study, two patient groups were evaluated: patients who responded to MLASC therapy (n=12) and patients who received placebo (n=12).
  • It also suggests that MLASCs may be a potential therapeutic option in both managing the disease but also, importantly, in limiting fistula formation.
  • We’re moving forward with confidence to assess the potential immunomodulatory and pro-regenerative therapeutic benefits of MLASCs as we advance the development of therapeutic options for patients.”

Akadeum Launches T Cell Activation and Expansion Using Positive Selection and Expands Leukopak Cell Isolation Product Lines at ASGCT 26th Annual Meeting

Retrieved on: 
Tuesday, May 16, 2023
Granulocyte, GMP, Gene, Centrifugation, ANN, T cell, Hematocrit, Cell therapy, Microbubble, Research, Cell, Immunotherapy, Doctor of Philosophy, Antibody, Human, PBMC, Patient, Magnet, Annual general meeting, Toxicology, Kinetics, Society, Vaccine

ANN ARBOR, Mich., May 16, 2023 /PRNewswire/ -- Akadeum Life Sciences, a global leader in buoyancy-based cell separation and activation technology, is announcing the launch of a new series of products for cell therapy research and development—enabling direct leukopak human immune cell isolation and T-cell activation/expansion kits at the American Society of Gene + Cell Therapy's 26th Annual Meeting from May 16-20, 2023 in Los Angeles, California. The new products expand Akadeum's lineup of Buoyancy-Activated Cell Sorting (BACS™) Microbubble buoyancy-based cell isolation kits, enabling the direct isolation of T cells (leveraging GMP-grade kit reagents) and peripheral blood mononuclear cells (PBMCs) from leukapheresis material without the need for lysis or density gradient centrifugation.

Key Points: 
  • The company that pioneered microbubbles for cell isolation is launching a first-of-its-kind product that uses microbubbles to activate T Cells and releasing the first GMP-grade microbubble product for T cell isolation.
  • This innovative advancement will give immunotherapy researchers the ability to produce high-yield, purified PBMCs and T cells in just one hour while remaining gentle on fragile immune cells.
  • Akadeum's product launch includes three new kits:
    All three kits use Akadeum's signature BACS™ Microbubble technology to drive powerful large-scale cell isolation, activation, and expansion—all while being gentle on cells.
  • The Human T Cell Activation & Expansion Kit does not compromise T cell expansion kinetics or activation strength while producing T cell populations with significantly less expression of exhaustion markers compared to competitors' products.

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process

Retrieved on: 
Sunday, May 14, 2023
Bankruptcy, Food additive, File, Chapter 11, Title 11, United States Code, MERU, Cell therapy, Cancer, NKT, History, Wind, APD, Patient, United States bankruptcy court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Security (finance), EU

BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (“Athenex” or the “Company”), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company’s assets across its primary businesses: Athenex Pharmaceutical Division (“APD”), Orascovery, and Cell Therapy.

Key Points: 
  • This will enable the Company to divest its assets and wind down the Athenex platform in an orderly fashion, while seeking to maximize value for its stakeholders.
  • The Company anticipates concluding the expedited sales process by July 1, 2023, with the Chapter 11 cases continuing thereafter to resolve claims.
  • While we explored every viable avenue to avoid this outcome, an orderly sales process represents the best path forward at this time.
  • MERU is serving as its financial advisor and Cassel Salpeter & Co., LLC as its investment banker.

Global CAR T Cell Therapy Competitive Landscape Report 2023: Insights About 250+ Companies and 500+ Drug Profiles - Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Friday, May 12, 2023
Health, Other Health, ASH, Therapy, Multiple myeloma, Cell therapy, New Drug Application, Roche, Clinical trial, NDA, Research, American Society of Hematology, Competition, Report, ORR, Huadong Medicine, Lymphoma, Acquisition, Patient, National Medical Products Administration, Annual general meeting, Cell, Mergers and acquisitions, Poster, Safety, NMPA, Society, Medicine, Pharmaceutical industry, Hematology

This report provides comprehensive insights about 250+ companies and 500+ drugs in CAR T - Cell Therapy Competitive landscape.

Key Points: 
  • This report provides comprehensive insights about 250+ companies and 500+ drugs in CAR T - Cell Therapy Competitive landscape.
  • It covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
  • The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends.
  • The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.